Numbers

Claude View

The Numbers

Brazil Potash is not priced on earnings — there are none. It trades as a binary option on the Autazes potash project: a $175M market cap sitting on $28M of cash, $140M of capitalized project spend, and roughly 13 months of runway at current burn. The single metric most likely to rerate or derate this stock is cash runway paired with financing cadence — every raise dilutes, every delay shortens the clock. Price has doubled off the July-2025 low but still sits ~48% below the analyst target of $6.17.

Price: Post-IPO volatility, reclaiming the $3 handle

The stock bled from the IPO-era $2.50 down to $1.25 by mid-July 2025 as post-listing lockup selling and the absence of any revenue catalyst weighed on the shares. A sharp September gap-up (likely tied to the Autazes installation-license news flow) pushed price back through the 50D, and from December onward the 50D has held above the 200D — a simple confirmation that trend has inverted. Current $3.24 sits comfortably above both MAs but still 16% below the 52W high of $3.99.

Income statement: There is no income statement

Net loss jumped 4x from FY23 to FY24 and another 12% to FY25 — but the reported loss is dominated by non-cash stock-based compensation ($42M in FY25, $36M in FY24), not operating cash spend. G&A roughly doubled to $12.7M as the company built out its public-company infrastructure. Quarterly losses peaked in Q4-24 and Q1-25 around the IPO and are now moderating — Q4-25 loss of $7M is the smallest in six quarters and a signal that the reporting-company scaffolding is now in place.

Cash burn: The only income-statement metric that matters

Cash operating burn roughly doubled — from $8.2M in FY23 to $13.2M in FY25 — while capex ramped 2.8x to $10.9M as project-engineering work intensified. Equity issuance financed essentially the entire story: $66.6M raised over three years, $62.7M in 2024–25 alone (IPO + follow-on). Once you strip out the $42M SBC, the cash loss in FY25 was only ~$10M — the real funding need is capex, not opex.

Cash runway: ~14 months at current burn, shorter if Autazes capex ramps

The math is simple: $27.8M cash at year-end, ~$24M annual cash outflow (OCF + capex) — that is 13.9 months of runway on current scope. But Autazes front-end engineering will push capex materially higher into construction-readiness, so the next financing round is a when-not-if event. The company has already demonstrated access — two IPO-era raises totalling $62.7M cleared without stress.

Balance sheet: The real story — $140M of project spend capitalized

The balance sheet is 83% PP&E — the entire enterprise is basically "capitalized Autazes development costs plus a small working-capital buffer." Liabilities are only $11.2M (with just $0.6M of debt), so leverage is effectively zero — GRO has not yet tapped project-finance markets. Retained-earnings deficit of -$198M reflects cumulative development spend since company formation.

Shares: 20% dilution in two years, more coming

Shares outstanding have climbed from 35.7M (FY23 year-end) to 54.2M today — 52% dilution in two years. The weighted-average diluted count lags the year-end count (42.5M vs 54.2M current), meaning FY26 reported EPS will dilute further even without new issuance. Every future raise compounds this effect; this is the single most important per-share variable to watch.

Peer comparison: Pre-revenue vs producing fertilizer majors

GRO is an order-of-magnitude smaller than every producing peer on every metric — no revenue, no earnings, no debt, and a market cap barely larger than Intrepid's cash position. The only peer it resembles structurally is IPI before its 2024 impairment (small US potash producer with minimal leverage), and even IPI generates ~$300M of revenue. The right way to read this table: GRO is not valued against NTR/MOS/ICL multiples — it is priced as a pre-production optionality asset against its own capex plan and resource base.

Valuation framing: What a single successful raise rerates

All 3 covering analysts rate GRO buy (1 strong-buy, 2 buy, 0 hold, 0 sell) with a target of $6.17 — roughly 90% upside from spot. That is consistent with a DCF that assumes Autazes reaches commercial production, not a near-term trading call.

Peer cross-check: Revenue scale vs market cap

Producing peers cluster tightly around a ~1.0x price-to-sales ratio. GRO sits off the trendline entirely because its market cap is pricing an option on future revenue, not current cash flows. This chart makes the narrative obvious: owning GRO is not a "cheap potash play" — it is a capital-markets and permitting bet.

Bottom line

The numbers confirm the core thesis: GRO is a pre-revenue development-stage name where the P&L is noise, the balance sheet is the story, and dilution is the clock. The numbers contradict any framing of GRO as a "cheap potash stock" — there is no operating cash flow to value, and every peer multiple breaks down against a $0 revenue base. What matters next quarter is (1) cash balance trajectory, (2) any capex acceleration signaling construction-readiness, and (3) the structure and size of the next capital raise — each equity round so far has been ~$30M and taken weighted-share count up by roughly 3–7M. A project-finance or strategic-partner deal that reduces future dilution would be the single biggest rerating catalyst.